Increase of neurofilament-H protein in sensory neurons in antiretroviral neuropathy: Evidence for a neuroprotective response mediated by the RNA-binding protein HuD

Pharmacol Res. 2016 Sep:111:23-33. doi: 10.1016/j.phrs.2016.05.026. Epub 2016 May 26.

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs) are key components of HIV/AIDS treatment to reduce viral load. However, antiretroviral toxic neuropathy has become a common peripheral neuropathy among HIV/AIDS patients leading to discontinuation of antiretroviral therapy, for which the underlying pathogenesis is uncertain. This study examines the role of neurofilament (NF) proteins in the spinal dorsal horn, DRG and sciatic nerve after NRTI neurotoxicity in mice treated with zalcitabine (2',3'-dideoxycitidine; ddC). ddC administration up-regulated NF-M and pNF-H proteins with no effect on NF-L. The increase of pNF-H levels was counteracted by the silencing of HuD, an RNA binding protein involved in neuronal development and differentiation. Sciatic nerve sections of ddC exposed mice showed an increased axonal caliber, concomitantly to a pNF-H up-regulation. Both events were prevented by HuD silencing. pNF-H and HuD colocalize in DRG and spinal dorsal horn axons. However, the capability of HuD to bind NF mRNA was not demonstrated, indicating the presence of an indirect mechanism of control of NF expression by HuD. RNA immunoprecipitation experiments showed the capability of HuD to bind the BDNF mRNA and the administration of an anti-BDNF antibody prevented pNF-H increase. These data indicate the presence of a HuD - BDNF - NF-H pathway activated as a regenerative response to the axonal damage induced by ddC treatment to counteract the antiretroviral neurotoxicity. Since analgesics clinically used to treat neuropathic pain are ineffective on antiretroviral neuropathy, a neuroregenerative strategy might represent a new therapeutic opportunity to counteract neurotoxicity and avoid discontinuation or abandon of NRTI therapy.

Keywords: Antiretroviral; BDNF; HuD; Neurofilament; Neuropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Retroviral Agents*
  • Antibodies / pharmacology
  • Brain-Derived Neurotrophic Factor / antagonists & inhibitors
  • Brain-Derived Neurotrophic Factor / genetics
  • Brain-Derived Neurotrophic Factor / metabolism
  • Disease Models, Animal
  • ELAV-Like Protein 4 / genetics
  • ELAV-Like Protein 4 / metabolism*
  • Ganglia, Spinal / metabolism
  • Ganglia, Spinal / pathology
  • Gene Silencing
  • Male
  • Mice
  • Neurofilament Proteins / metabolism*
  • Neuroprotective Agents / pharmacology
  • Oligonucleotides, Antisense / genetics
  • Oligonucleotides, Antisense / metabolism
  • Protein Kinase C / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Sciatic Nerve / metabolism
  • Sciatic Nerve / pathology
  • Sciatic Neuropathy / chemically induced
  • Sciatic Neuropathy / genetics
  • Sciatic Neuropathy / metabolism
  • Sciatic Neuropathy / prevention & control
  • Sensory Receptor Cells / metabolism*
  • Sensory Receptor Cells / pathology
  • Signal Transduction
  • Spinal Cord / metabolism
  • Spinal Cord / pathology
  • Up-Regulation
  • Zalcitabine*

Substances

  • Anti-Retroviral Agents
  • Antibodies
  • Brain-Derived Neurotrophic Factor
  • ELAV-Like Protein 4
  • Elavl4 protein, mouse
  • Neurofilament Proteins
  • Neuroprotective Agents
  • Oligonucleotides, Antisense
  • RNA, Messenger
  • neurofilament protein H
  • Zalcitabine
  • protein kinase C gamma
  • Protein Kinase C